Antonello Mai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2000827/publications.pdf

Version: 2024-02-01

351 papers	15,744 citations	16451 64 h-index	31849 101 g-index
375 all docs	375 docs citations	375 times ranked	22616 citing authors

#	Article	IF	Citations
1	The Nitrobenzoxadiazole Derivative NBDHEX Behaves as Plasmodium falciparum Gametocyte Selective Inhibitor with Malaria Parasite Transmission Blocking Activity. Pharmaceuticals, 2022, 15, 168.	3.8	3
2	A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression. International Journal of Antimicrobial Agents, 2022, 59, 106526.	2.5	12
3	Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription. Nucleic Acids Research, 2022, 50, 2566-2586.	14.5	12
4	Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. Theranostics, 2022, 12, 2427-2444.	10.0	12
5	Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1339-1359.	7.3	11
6	Inhibition of PKCÎ¸ Improves Dystrophic Heart Phenotype and Function in a Novel Model of DMD Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 2256.	4.1	1
7	Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 973-985.	5.2	2
8	Biochemical Functions and Clinical Characterizations of the Sirtuins in Diabetes-Induced Retinal Pathologies. International Journal of Molecular Sciences, 2022, 23, 4048.	4.1	11
9	Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibroâ€adipogenic progenitors. EMBO Reports, 2022, 23, e54721.	4.5	7
10	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. European Journal of Medicinal Chemistry, 2022, 237, 114410.	5.5	15
11	Sirtuin modulators: past, present, and future perspectives. Future Medicinal Chemistry, 2022, 14, 915-939.	2.3	24
12	Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. Frontiers in Endocrinology, 2022, 13, .	3.5	4
13	Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni. ACS Infectious Diseases, 2022, 8, 1356-1366.	3.8	13
14	Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5. Journal of Medicinal Chemistry, 2022, 65, 9580-9606.	6.4	21
15	Downregulation of miRâ€326 and its host gene Î²â€arrestin1 induces proâ€survival activity of E2F1 and promotes medulloblastoma growth. Molecular Oncology, 2021, 15, 523-542.	4.6	8
16	Novel Pyridineâ€Based Hydroxamates and 2â€²â€Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem, 2021, 16, 989-999.	3.2	8
17	Sirtuins. , 2021, , 1-15.		0
18	Amphetamine Modulation of Long-Term Object Recognition Memory in Rats: Influence of Stress. Frontiers in Pharmacology, 2021, 12, 644521.	3.5	1

#	Article	IF	Citations
19	Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer. Cancers, 2021, 13, 543.	3.7	10
20	The Two-Faced Role of SIRT6 in Cancer. Cancers, 2021, 13, 1156.	3.7	33
21	SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes. Cells, 2021, 10, 1126.	4.1	16
22	Emerging Therapeutic Potential of SIRT6 Modulators. Journal of Medicinal Chemistry, 2021, 64, 9732-9758.	6.4	38
23	Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Gastroenterology, 2021, 161, 1584-1600.	1.3	50
24	Histoneâ€deacetylase 8 drives the immune response and the growth of glioma. Glia, 2021, 69, 2682-2698.	4.9	14
25	Polycomb Repressive Complex 2 Modulation through the Development of EZH2â€“EED Interaction Inhibitors and EED Binders. Journal of Medicinal Chemistry, 2021, 64, 11774-11797.	6.4	25
26	Anti-influenza A virus activity and structureâ€“activity relationship of a series of nitrobenzoxadiazole derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 2128-2138.	5.2	5
27	Mass spectrometry enables the discovery of inhibitors of an LPS transport assembly via disruption of proteinâ€“protein interactions. Chemical Communications, 2021, 57, 10747-10750.	4.1	6
28	First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. Journal of Medicinal Chemistry, 2021, 64, 17031-17050.	6.4	7
29	Sirtuins. , 2021, , 1422-1435.		0
30	Sex-dependent Effects of the Drugs of Abuse Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone on Fear Memory Generalization in Rats. Neuroscience, 2021, , .	2.3	2
31	Epigenetic polypharmacology: A new frontier for epiâ€drug discovery. Medicinal Research Reviews, 2020, 40, 190-244.	10.5	74
32	Inhibition of class I HDACs imprints adipogenesis toward oxidative and brown-like phenotype. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158594.	2.4	11
33	Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). European Journal of Medicinal Chemistry, 2020, 207, 112750.	5.5	12
34	From PARP1 to TNKS2 Inhibition: A Structure-Based Approach. ACS Medicinal Chemistry Letters, 2020, 11, 862-868.	2.8	8
35	Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. Molecules, 2020, 25, 3122.	3.8	4
36	Lysine Acetyltransferase Inhibitors From Natural Sources. Frontiers in Pharmacology, 2020, 11, 1243.	3.5	22

#	Article	IF	Citations
37	CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. Frontiers in Pharmacology, 2020, 11, 1230.	3.5	20
38	Diphenylene Iodonium Is a Noncovalent MAO Inhibitor: A Biochemical and Structural Analysis. ChemMedChem, 2020, 15, 1394-1397.	3.2	4
39	Detrimental effects of the â€˜bath saltâ€™ methylenedioxypyrovalerone on social play behavior in male rats. Neuropsychopharmacology, 2020, 45, 2012-2019.	5.4	5
40	Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes. International Journal of Molecular Sciences, 2020, 21, 3659.	4.1	8
41	The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. Frontiers in Oncology, 2020, 10, 820.	2.8	8
42	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Medicinal Chemistry Letters, 2020, 11, 977-983.	2.8	49
43	Sirtuin modulators: where are we now? A review of patents from 2015 to 2019. Expert Opinion on Therapeutic Patents, 2020, 30, 389-407.	5.0	39
44	The Innovative Potential of Statins in Cancer: New Targets for New Therapies. Frontiers in Chemistry, 2020, 8, 516.	3.6	73
45	Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2020, 14, e0008332.	3.0	11
46	Targeting histone acetylation/deacetylation in parasites: an update (2017â€“2020). Current Opinion in Chemical Biology, 2020, 57, 65-74.	6.1	35
47	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447.	3.7	8
48	A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. Redox Biology, 2020, 32, 101466.	9.0	62
49	Tranylcypromineâ€Based LSD1 Inhibitors: Structureâ€Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. ChemMedChem, 2020, 15, 643-658.	3.2	18
50	Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene. Human Genetics, 2020, 139, 227-245.	3.8	16
51	Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer. Frontiers in Oncology, 2020, 10, 474.	2.8	49
52	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acidâ€“induced differentiation. Science Advances, 2020, 6, eaax2746.	10.3	56
53	Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization. ACS Chemical Biology, 2020, 15, 1349-1357.	3.4	4
54	HAT inhibitors in cancer therapy. , 2020, , 51-80.		2

#	Article	IF	Citations
55	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€MEF2 complexes. EMBO Reports, 2020, 21, e51028.	4.5	1
56	Title is missing!. , 2020, 14, e0008332.		0
57	Title is missing!. , 2020, 14, e0008332.		0
58	Title is missing!. , 2020, 14, e0008332.		0
59	Title is missing!. , 2020, 14, e0008332.		0
60	H19-Dependent Transcriptional Regulation of Î²3 and Î²4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 4012.	4.1	22
61	The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells. Scientific Reports, 2019, 9, 15925.	3.3	35
62	Structureâ€“Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from Schistosoma mansoni (SmSirt2). Journal of Medicinal Chemistry, 2019, 62, 8733-8759.	6.4	18
63	Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. Clinical Epigenetics, 2019, 11, 11.	4.1	55
64	Epigenetic Pharmacology in Regenerative Medicine (Epi-Drugs). , 2019, , 405-444.		0
65	Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. Molecular Neurobiology, 2019, 56, 8018-8034.	4.0	20
66	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	4.1	30
67	Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology, 2019, 50, 89-100.	6.1	23
68	Comparison of the effects of synthetic and plant-derived mTOR regulators on healthy human ovarian cells. European Journal of Pharmacology, 2019, 854, 70-78.	3.5	3
69	Statins and Histone Deacetylase Inhibitors Affect Lamin A/C â€“ Histone Deacetylase 2 Interaction in Human Cells. Frontiers in Cell and Developmental Biology, 2019, 7, 6.	3.7	23
70	The emerging role of epigenetics in human autoimmune disorders. Clinical Epigenetics, 2019, 11, 34.	4.1	200
71	Î±,Î³-Diketocarboxylic Acids and Their Esters Act as Carbonic Anhydrase IX and XII Selective Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 661-665.	2.8	18
72	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. International Journal of Molecular Sciences, 2019, 20, 5654.	4.1	16

#	Article	IF	Citations
73	Inhibition of Histone Demethylases LSD1 and UTX Regulates ERÎ± Signaling in Breast Cancer. Cancers, 2019, 11, 2027.	3.7	34
74	Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone (MDPV) Induce Generalization of Fear Memory in Rats. Frontiers in Molecular Neuroscience, 2019, 12, 292.	2.9	9
75	Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells. European Journal of Medicinal Chemistry, 2019, 163, 722-735.	5.5	15
76	Intergenerational inheritance of high fat diet-induced cardiac lipotoxicity in Drosophila. Nature Communications, 2019, 10, 193.	12.8	49
77	Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. Journal of Psychopharmacology, 2019, 33, 392-405.	4.0	21
78	Identification of novel quinazoline derivatives as potent antiplasmodial agents. European Journal of Medicinal Chemistry, 2019, 161, 277-291.	5.5	44
79	Effect of Î±-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3H)-ones. Journal of Medicinal Chemistry, 2019, 62, 604-621.	6.4	14
80	Epigenetic Metalloenzymes. Current Medicinal Chemistry, 2019, 26, 2748-2785.	2.4	12
81	DNA Methylation: Biological Implications and Modulation of Its Aberrant Dysregulation. RNA Technologies, 2019, , 295-331.	0.3	1
82	Lysine acetyltransferase inhibitors: structureâ€“activity relationships and potential therapeutic implications. Future Medicinal Chemistry, 2018, 10, 1067-1091.	2.3	24
83	Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170150.	4.0	13
84	Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches. Journal of Computer-Aided Molecular Design, 2018, 32, 435-458.	2.9	15
85	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53.	12.8	175
86	KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2. Clinical Epigenetics, 2018, 10, 44.	4.1	12
87	RIP1â€“HAT1â€“SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. Clinical Cancer Research, 2018, 24, 2886-2900.	7.0	40
88	Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice. Neuroscience, 2018, 379, 228-238.	2.3	22
89	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 2018, 9, 25647-25660.	1.8	13
90	EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers. Frontiers in Pediatrics, 2018, 6, 328.	1.9	14

#	Article	IF	Citations
91	Application of Small Epigenetic Modulators in Pediatric Medulloblastoma. Frontiers in Pediatrics, 2018, 6, 370.	1.9	12
92	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	6.3	75
93	Six Years (2012â€“2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2â€Pyridone Compounds. Chemical Record, 2018, 18, 1818-1832.	5.8	76
94	Trends of LSD1 inhibitors in viral infections. Future Medicinal Chemistry, 2018, 10, 1133-1136.	2.3	10
95	HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal. Scientific Reports, 2018, 8, 8492.	3.3	23
96	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	4.1	33
97	Altered modulation of lamin A/Câ€HDAC2 interaction and p21 expression during oxidative stress response in HGPS. Aging Cell, 2018, 17, e12824.	6.7	39
98	Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers. Psychopharmacology, 2018, 235, 2831-2846.	3.1	11
99	Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, 2018, 9, 25630-25646.	1.8	5
100	A new nitrobenzoxadiazole-based GSTP1-1 inhibitor with a previously unheard of mechanism of action and high stability. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 240-247.	5.2	17
101	Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Scientific Reports, 2017, 7, 44079.	3.3	57
102	Metabolite profiling of ascidian Styela plicata using LCâ€“MS with multivariate statistical analysis and their antitumor activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 614-623.	5.2	17
103	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. Journal of Medicinal Chemistry, 2017, 60, 4780-4804.	6.4	71
104	Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structureâ€“Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. Journal of Medicinal Chemistry, 2017, 60, 2344-2360.	6.4	82
105	Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. European Journal of Medicinal Chemistry, 2017, 134, 316-333.	5.5	24
106	EZH2 inhibitors: a patent review (2014-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 797-813.	5.0	40
107	The relevance of K i calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. European Journal of Medicinal Chemistry, 2017, 136, 480-486.	5.5	7
108	Structureâ€“Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. ChemMedChem, 2017, 12, 1359-1368.	3.2	11

#	Article	IF	Citations
109	Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Bioorganic and Medicinal Chemistry, 2017, 25, 847-856.	3.0	11
110	Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. Angewandte Chemie - International Edition, 2017, 56, 1007-1011.	13.8	125
111	Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. Angewandte Chemie, 2017, 129, 1027-1031.	2.0	4
112	Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice. Neuroscience Letters, 2017, 656, 120-125.	2.1	22
113	Crystal structures of the mitochondrial deacylase Sirtuin 4 reveal isoform-specific acyl recognition and regulation features. Nature Communications, 2017, 8, 1513.	12.8	80
114	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clinical Epigenetics, 2017, 9, 59.	4.1	118
115	Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases. International Journal of Obesity, 2017, 41, 289-298.	3.4	41
116	Essential Oil Extraction, Chemical Analysis and Anti-Candida Activity of Calamintha nepeta (L.) Savi subsp. glandulosa (Req.) Ballâ€"New Approaches. Molecules, 2017, 22, 203.	3.8	30
117	The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget, 2017, 8, 68557-68570.	1.8	49
118	LSD1 inhibitors: a patent review (2010-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 565-580.	5.0	46
119	Sirtuin functions and modulation: from chemistry to the clinic. Clinical Epigenetics, 2016, 8, 61.	4.1	291
120	Chemical epigenetics to assess the role of HDAC1â€“3 inhibition in macrophage pro-inflammatory gene expression. MedChemComm, 2016, 7, 2184-2190.	3.4	7
121	The emerging role of lysine methyltransferase SETD8 in human diseases. Clinical Epigenetics, 2016, 8, 102.	4.1	77
122	Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors. ChemMedChem, 2016, 11, 1680-1685.	3.2	18
123	MC1568 inhibits HDAC6/8 activity and influenza A virus replication in lung epithelial cells: role of Hsp90 acetylation. Future Medicinal Chemistry, 2016, 8, 2017-2031.	2.3	33
124	The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell, 2016, 167, 1145-1149.	28.9	404
125	Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features. Science Advances, 2016, 2, e1601017.	10.3	61
126	Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1Î² and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model. Autoimmunity, 2016, 49, 155-165.	2.6	20

#	Article	IF	Citations
127	The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. Biochemical Pharmacology, 2016, 102, 130-140.	4.4	46
128	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 1471-1491.	6.4	60
129	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517.	6.4	70
130	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget, 2016, 7, 11332-11348.	1.8	49
131	Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. American Journal of Cancer Research, 2016, 6, 859-75.	1.4	18
132	Targeting Lysine Deacetylases (KDACs) in Parasites. PLoS Neglected Tropical Diseases, 2015, 9, e0004026.	3.0	47
133	Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. European Journal of Medicinal Chemistry, 2015, 94, 163-174.	5.5	28
134	Enzyme kinetics and inhibition of histone acetyltransferase KAT8. European Journal of Medicinal Chemistry, 2015, 105, 289-296.	5.5	31
135	Sirtuin modulators: an updated patent review (2012 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 5-15.	5.0	46
136	Sirtuin function in aging heart and vessels. Journal of Molecular and Cellular Cardiology, 2015, 83, 55-61.	1.9	83
137	Pyrrole- and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells. MedChemComm, 2015, 6, 665-670.	3.4	24
138	Interplay among nucleosomal DNA, histone tails, and corepressor CoREST underlies LSD1-mediated H3 demethylation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2752-2757.	7.1	71
139	SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy, 2015, 11, 253-270.	9.1	223
140	New Insights on the Mechanism of Quinoline-based DNA Methyltransferase Inhibitors. Journal of Biological Chemistry, 2015, 290, 6293-6302.	3.4	50
141	Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells. Journal of Medicinal Chemistry, 2015, 58, 4073-4079.	6.4	55
142	Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 599-613.	5.0	63
143	A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochemical Pharmacology, 2015, 95, 16-27.	4.4	29
144	A Novel Cell-Permeable, Selective, and Noncompetitive Inhibitor of KAT3 Histone Acetyltransferases from a Combined Molecular Pruning/Classical Isosterism Approach. Journal of Medicinal Chemistry, 2015, 58, 2779-2798.	6.4	48

#	Article	IF	Citations
145	Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. European Neuropsychopharmacology, 2015, 25, 2036-2048.	0.7	51
146	Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents. ACS Chemical Biology, 2015, 10, 2589-2597.	3.4	54
147	Synthesis and structureâ€“activity relationship of new cytotoxic agents targeting human glutathione-S-transferases. European Journal of Medicinal Chemistry, 2015, 89, 156-171.	5.5	32
148	Identification of Structural Features of 2â€Alkylideneâ€1,3â€Dicarbonyl Derivatives that Induce Inhibition and/or Activation of Histone Acetyltransferases KAT3B/p300 and KAT2B/PCAF. ChemMedChem, 2015, 10, 144-157.	3.2	21
149	Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Medicinal Chemistry Letters, 2015, 6, 173-177.	2.8	16
150	A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. Oncotarget, 2015, 6, 4126-4143.	1.8	22
151	DNA Methyltransferases Inhibitors from Natural Sources. Current Topics in Medicinal Chemistry, 2015, 16, 680-696.	2.1	56
152	Abstract 2946: Effects of two novel quinoline-based non-nucleoside DNA methyltransferase inhibitors against bone sarcomas. , 2015, , .		0
153	Properly Substituted Analogues of BIX-01294 Lose Inhibition of G9a Histone Methyltransferase and Gain Selective Anti-DNA Methyltransferase 3A Activity. PLoS ONE, 2014, 9, e96941.	2.5	35
154	PRMT1 arginine methyltransferase accumulates in cytoplasmic bodies that respond to selective inhibition and DNA damage. European Journal of Histochemistry, 2014, 58, 2389.	1.5	9
155	Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. Journal of Molecular Cell Biology, 2014, 6, 116-127.	3.3	31
156	The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene, 2014, 33, 4173-4184.	5.9	61
157	Sirtuin modulators control reactive gliosis in an in vitro model of AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Pharmacology, 2014, 5, 89.	3.5	56
158	Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2014, 86, 352-363.	5.5	50
159	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. Cancer Research, 2014, 74, 2328-2339.	0.9	33
160	Quinolineâ€Based p300 Histone Acetyltransferase Inhibitors with Proâ€apoptotic Activity in Human Leukemia U937 Cells. ChemMedChem, 2014, 9, 542-548.	3.2	29
161	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. International Journal of Biochemistry and Cell Biology, 2014, 50, 112-122.	2.8	23
162	IÎºB Kinase Îµ Targets Interferon Regulatory Factor 1 in Activated T Lymphocytes. Molecular and Cellular Biology, 2014, 34, 1054-1065.	2.3	33

#	Article	IF	Citations
163	Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 â€“ 2013). Expert Opinion on Therapeutic Patents, 2014, 24, 401-415.	5.0	40
164	Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: Enzyme and cellular studies. European Journal of Medicinal Chemistry, 2014, 80, 569-578.	5.5	54
165	Targeting Epigenetics in Drug Discovery. ChemMedChem, 2014, 9, 415-417.	3.2	12
166	Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. Biochemical Pharmacology, 2014, 91, 181-190.	4.4	24
167	Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells. Journal of Medicinal Chemistry, 2014, 57, 701-713.	6.4	111
168	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6259-6265.	6.4	102
169	Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities. Journal of Medicinal Chemistry, 2014, 57, 42-55.	6.4	105
170	Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer, 2014, 14, 139.	2.6	61
171	Novel inhibitors of human histone deacetylases: Design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3797-3801.	2.2	35
172	Exploring the Role of 2-Chloro-6-fluoro Substitution in 2-Alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: Effects in HIV-1-Infected Cells and in HIV-1 Reverse Transcriptase Enzymes. Journal of Medicinal Chemistry, 2014, 57, 5212-5225.	6.4	17
173	Epigenetic drugs targeting cccDNA-bound chromatin modifying enzymes silence HBV transcription and inhibit viral replication. Digestive and Liver Disease, 2014, 46, e25.	0.9	0
174	The Histone Acetylase Activator Pentadecylidenemalonate 1b Rescues Proliferation and Differentiation in the Human Cardiac Mesenchymal Cells of Type 2 Diabetic Patients. Diabetes, 2014, 63, 2132-2147.	0.6	66
175	Histone Modifications, Stem Cells and Prostate Cancer. Current Pharmaceutical Design, 2014, 20, 1687-1697.	1.9	11
176	Screen of Pseudopeptidic Inhibitors of Human Sirtuins 1â€“3: Two Lead Compounds with Antiproliferative Effects in Cancer Cells. Journal of Medicinal Chemistry, 2013, 56, 6681-6695.	6.4	36
177	Oxidative Stress and Epigenetic Regulation in Ageing and Age-Related Diseases. International Journal of Molecular Sciences, 2013, 14, 17643-17663.	4.1	183
178	tertâ€Butylcarbamateâ€Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. ChemMedChem, 2013, 8, 800-811.	3.2	16
179	Novel benzofuranâ€“chromone and â€“coumarin derivatives: synthesis and biological activity in K562 human leukemia cells. MedChemComm, 2013, 4, 1571.	3.4	41
180	Reactivity of 4â€Vinylâ€2Hâ€1â€benzopyranâ€2â€ones in Dielsâ€“Alder Cycloaddition Reactions: Access to Coumarinâ€Based Polycycles with Cdc25 Phosphataseâ€Inhibiting Activity. European Journal of Organic Chemistry, 2013, 2013, 2869-2877.	2.4	12

#	Article	IF	Citations
181	Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase. ACS Chemical Biology, 2013, 8, 1677-1682.	3.4	60
182	Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue. Diabetes, 2013, 62, 732-742.	0.6	196
183	Detrimental Effect of Class-selective Histone Deacetylase Inhibitors during Tissue Regeneration following Hindlimb Ischemia. Journal of Biological Chemistry, 2013, 288, 22915-22929.	3.4	29
184	A Nitric Oxide-dependent Cross-talk between Class I and III Histone Deacetylases Accelerates Skin Repair. Journal of Biological Chemistry, 2013, 288, 11004-11012.	3.4	74
185	Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29. PLoS ONE, 2013, 8, e55786.	2.5	56
186	P300/CBP Associated Factor Regulates Nitroglycerin-Dependent Arterial Relaxation by N ^{Îµ} -Lysine Acetylation of Contractile Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2435-2443.	2.4	29
187	Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2284-93.	7.1	39
188	Identification of Small-Molecule Enhancers of Arginine Methylation Catalyzed by Coactivator-Associated Arginine Methyltransferase 1. Journal of Medicinal Chemistry, 2012, 55, 9875-9890.	6.4	22
189	Screening Assays for Epigenetic Targets Using Native Histones as Substrates. Journal of Biomolecular Screening, 2012, 17, 18-26.	2.6	17
190	Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead. MedChemComm, 2012, 3, 298-304.	3.4	7
191	p300/CBP-Associated Factor Selectively Regulates the Extinction of Conditioned Fear. Journal of Neuroscience, 2012, 32, 11930-11941.	3.6	82
192	Histone Deacetylase Inhibitors: Structure-Based Modeling and Isoform-Selectivity Prediction. Journal of Chemical Information and Modeling, 2012, 52, 2215-2235.	5.4	26
193	Revelations into resveratrol's mechanism. Nature Medicine, 2012, 18, 500-501.	30.7	14
194	Benzodeazaoxaflavins as Sirtuin Inhibitors with Antiproliferative Properties in Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 8193-8197.	6.4	33
195	An Analog of BIX-01294 Selectively Inhibits a Family of Histone H3 Lysine 9 Jumonji Demethylases. Journal of Molecular Biology, 2012, 416, 319-327.	4.2	53
196	Carprofen Analogues as Sirtuin Inhibitors: Enzyme and Cellular Studies. ChemMedChem, 2012, 7, 1905-1908.	3.2	14
197	The emerging role of histone lysine demethylases in prostate cancer. Molecular Cancer, 2012, 11, 52.	19.2	72
198	Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 10937-10947.	6.4	84

#	Article	IF	Citations
199	Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie, 2012, 94, 2308-2313.	2.6	27
200	6-(Arylmethyl)pyrimidin-4(3H)-ones: anthology and prospects of highly efficient anti-HIV agents. Russian Chemical Bulletin, 2012, 61, 1399-1418.	1.5	11
201	2-(Alkyl/Aryl)Amino-6-Benzylpyrimidin-4(3H)-ones as Inhibitors of Wild-Type and Mutant HIV-1: Enantioselectivity Studies. Journal of Medicinal Chemistry, 2012, 55, 3558-3562.	6.4	29
202	BLUEPRINT to decode the epigenetic signature written in blood. Nature Biotechnology, 2012, 30, 224-226.	17.5	323
203	Photoactivable peptides for identifying enzymeâ€“substrate and proteinâ€“protein interactions. Chemical Communications, 2011, 47, 1488-1490.	4.1	5
204	Epigenetic modulation of PGC-1Î± activity by GCN5 inhibitors: WO2010007085. Expert Opinion on Therapeutic Patents, 2011, 21, 1651-1656.	5.0	9
205	Modulation of Cell Differentiation, Proliferation, and Tumor Growth by Dihydrobenzyloxopyrimidine Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 5927-5936.	6.4	13
206	CS03-5. IRF-1 phosphorylation by I-kappa-B kinase epsilon impairs IFN beta stimulation in activated CD4+ T cells.. Cytokine, 2011, 56, 9.	3.2	0
207	Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin. Biochemical and Biophysical Research Communications, 2011, 408, 630-634.	2.1	26
208	Specific Control of Pancreatic Endocrine Î²- and Î´-Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9. Diabetes, 2011, 60, 2861-2871.	0.6	119
209	Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1H-Pyrrol-3-yl)-2-oxazolidinones. Journal of Medicinal Chemistry, 2011, 54, 8228-8232.	6.4	33
210	Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 3051-3064.	6.4	50
211	Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. Aids, 2011, 25, 1347-1356.	2.2	74
212	Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3'-C-methyladenosine in leukaemia cells. International Journal of Oncology, 2011, 38, 1427-36.	3.3	7
213	Application of 3Î¼m particle-based amylose-derived chiral stationary phases for the enantioseparation of potential histone deacetylase inhibitors. Journal of Chromatography A, 2011, 1218, 8394-8398.	3.7	19
214	Novel 3,5-Bis(bromohydroxybenzylidene)piperidin-4-ones as Coactivator-Associated Arginine Methyltransferase 1 Inhibitors: Enzyme Selectivity and Cellular Activity. Journal of Medicinal Chemistry, 2011, 54, 4928-4932.	6.4	65
215	Diarylpyrimidineâ€“Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level. Journal of Medicinal Chemistry, 2011, 54, 3091-3096.	6.4	47
216	Novel Cinnamyl Hydroxyamides and 2â€²Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. ChemMedChem, 2011, 6, 698-712.	3.2	17

#	Article	IF	Citations
217	Biological Effects of MC2050, a Quinazolineâ€Based PARPâ€1 Inhibitor, in Human Neuroblastoma and EBVâ€Positive Burkittâ€²s Lymphoma Cells. ChemMedChem, 2011, 6, 606-611.	3.2	12
218	Identification of Smallâ€Molecule Inhibitors of the XendoU Endoribonucleases Family. ChemMedChem, 2011, 6, 1797-1805.	3.2	8
219	A Photoreactive Small-Molecule Probe for 2-Oxoglutarate Oxygenases. Chemistry and Biology, 2011, 18, 642-654.	6.0	46
220	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). Bioorganic and Medicinal Chemistry, 2011, 19, 3690-3701.	3.0	29
221	Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: Coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. Bioorganic and Medicinal Chemistry, 2011, 19, 3659-3668.	3.0	30
222	HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. Cancer Research, 2011, 71, 4412-4422.	0.9	159
223	N ^{Îµ} -lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2795-2800.	7.1	93
224	Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes and Cancer, 2011, 2, 663-679.	1.9	177
225	Sirtinol Treatment Reduces Inflammation in Human Dermal Microvascular Endothelial Cells. PLoS ONE, 2011, 6, e24307.	2.5	61
226	Identification of specific and semi-specific SIRT inhibitors through computer-aided studies. Aging, 2011, 3, 819-820.	3.1	1
227	Characterization of Sirtuin Inhibitors in Nematodes Expressing a Muscular Dystrophy Protein Reveals Muscle Cell and Behavioral Protection by Specific Sirtinol Analogues. Journal of Medicinal Chemistry, 2010, 53, 1407-1411.	6.4	48
228	The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovascular Research, 2010, 87, 73-82.	3.8	43
229	The specific character of the reaction of derivatives of 2-thioxo-2,3-dihydropyrimidin-4(1H)-one with iodomethane and alkyl chloromethyl sulfides. Chemistry of Heterocyclic Compounds, 2010, 46, 200-205.	1.2	1
230	Design, Synthesis and Biological Evaluation of Carboxy Analogues of Arginine Methyltransferase Inhibitorâ€…1 (AMIâ€1). ChemMedChem, 2010, 5, 398-414.	3.2	60
231	Identification of Triâ€and Tetracyclic Pyrimidinediones as Sirtuin Inhibitors. ChemMedChem, 2010, 5, 674-677.	3.2	40
232	Synthesis and Biological Characterization of Amidopropenyl Hydroxamates as HDAC Inhibitors. ChemMedChem, 2010, 5, 1359-1372.	3.2	13
233	Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics - Clinical Applications, 2010, 4, 71-83.	1.6	30
234	Nitric Oxide Determines Mesodermic Differentiation of Mouse Embryonic Stem Cells by Activating Class IIa Histone Deacetylases: Potential Therapeutic Implications in a Mouse Model of Hindlimb Ischemia. Stem Cells, 2010, 28, 431-442.	3.2	50

#	Article	IF	Citations
235	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene, 2010, 29, 105-116.	5.9	73
236	Lysine Acetylation Regulates Brutonâ€™s Tyrosine Kinase in B Cell Activation. Journal of Immunology, 2010, 184, 244-254.	0.8	15
237	HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. Journal of Molecular Endocrinology, 2010, 45, 219-228.	2.5	53
238	Histone Deacetylase-3 Activation Promotes Tumor Necrosis Factor-Î± (TNF-Î±) Expression in Cardiomyocytes during Lipopolysaccharide Stimulation. Journal of Biological Chemistry, 2010, 285, 9429-9436.	3.4	89
239	Combining 3-D Quantitative Structureâ^'Activity Relationship with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors. Journal of Chemical Information and Modeling, 2010, 50, 662-676.	5.4	54
240	Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacological Research, 2010, 62, 3-10.	7.1	39
241	TNF/p38Î±/Polycomb Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle Regeneration. Cell Stem Cell, 2010, 7, 455-469.	11.1	346
242	Chemogenomic profiling of the cellular effects associated with histone H3 acetylation impairment by a quinoline-derived compound. Genomics, 2010, 96, 272-280.	2.9	11
243	Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. Journal of the American Chemical Society, 2010, 132, 6827-6833.	13.7	261
244	Small-molecule chromatin-modifying agents: therapeutic applications. Epigenomics, 2010, 2, 307-324.	2.1	29
245	Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 822-839.	6.4	32
246	Evaluation of Histone Deacetylases as Drug Targets in Huntingtonâ€™s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.. PLOS Currents, 2010, 2, RRN1172.	1.4	33
247	Histone Deacetylase inhibitors modulate mitochondrial biogenesis in skeletal muscle. FASEB Journal, 2010, 24, lb119.	0.5	1
248	Correction for Colussi et al., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1679-1679.	7.1	2
249	Chiral HPLC separation and absolute configuration of novel Sâ€DABO derivatives. Chirality, 2009, 21, 604-612.	2.6	12
250	Pyroleâ€Based Hydroxamates and 2â€Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. ChemMedChem, 2009, 4, 1411-1415.	3.2	9
251	Histone postâ€translational modifications by HPLCâ€ESIâ€MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics, 2009, 9, 5437-5445.	2.2	25
252	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€“MEF2 complexes. EMBO Reports, 2009, 10, 776-782.	4.5	125

#	Article	IF	Citations
253	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene, 2009, 28, 781-791.	5.9	244
254	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1132-1135.	2.2	63
255	Reactions of 6-benzyl-5-methyl-2-(methylsulfanyl)pyrimidin-4(3H)-one with aliphatic and aliphatic-aromatic amines. Russian Journal of Organic Chemistry, 2009, 45, 773-776.	0.8	4
256	Stereoselective synthesis of 2-substituted 6-[1-(2,6-difluorophenyl)ethyl]-5-methylpyrimidin-4(3H)-ones. Russian Journal of Organic Chemistry, 2009, 45, 1531-1534.	0.8	1
257	Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. International Journal of Biochemistry and Cell Biology, 2009, 41, 199-213.	2.8	177
258	New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. International Journal of Biochemistry and Cell Biology, 2009, 41, 235-247.	2.8	24
259	Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5496-5504.	6.4	147
260	"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology, 2009, 6, 52.	2.0	100
261	Histone acetyltransferase inhibitors and preclinical studies. Expert Opinion on Therapeutic Patents, 2009, 19, 761-774.	5.0	93
262	Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise. Current Pharmaceutical Design, 2009, 15, 3940-3957.	1.9	74
263	Non-Cancer Uses of Histone Deacetylase Inhibitors: Effects on Infectious Diseases and β-Hemoglobinopathies+. Current Topics in Medicinal Chemistry, 2009, 9, 272-291.	2.1	44
264	Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro.. Blood, 2009, 114, 1978-1978.	1.4	0
265	Substrate-Induced Stable Enzyme-Inhibitor Complex Formation Allows Tight Binding of Novel 2-Aminopyrimidin-4(3H)-ones to Drug-Resistant HIV-1 Reverse Transcriptase Mutants. ChemMedChem, 2008, 3, 1412-1418.	3.2	8
266	Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies. European Journal of Medicinal Chemistry, 2008, 43, 621-632.	5.5	39
267	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2530-2535.	2.2	22
268	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2788-2792.	2.2	96
269	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a Series of Anti-HIV-1 Agents of the Dihydro-alkoxy-benzyl-oxopyrimidine Family with Peculiar Structureâ”Activity Relationship Profile. Journal of Medicinal Chemistry, 2008, 51, 4641-4652.	6.4	52
270	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2030-2038.	4.1	48

#	Article	IF	Citations
271	Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 2279-2290.	6.4	133
272	Histone deacetylase inhibitors and hemoglobin F induction in Î²-thalassemia. International Journal of Biochemistry and Cell Biology, 2008, 40, 2341-2347.	2.8	14
273	HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19183-19187.	7.1	234
274	Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling. Circulation Research, 2008, 102, 51-58.	4.5	114
275	Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 1908-1919.	3.4	95
276	Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 2007, 51, 1109-1111.	3.2	32
277	Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. Molecular Pharmacology, 2007, 72, 1111-1123.	2.3	30
278	Small Molecule Inhibitors of Histone Arginine Methyltransferases:â€‰ Homology Modeling, Molecular Docking, Binding Mode Analysis, and Biological Evaluations. Journal of Medicinal Chemistry, 2007, 50, 1241-1253.	6.4	98
279	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. International Journal of Biochemistry and Cell Biology, 2007, 39, 1510-1522.	2.8	13
280	Synthesis and Biological Properties of Novel 2-Aminopyrimidin-4(3H)-ones Highly Potent against HIV-1 Mutant Strains. Journal of Medicinal Chemistry, 2007, 50, 5412-5424.	6.4	55
281	The therapeutic uses of chromatin-modifying agents. Expert Opinion on Therapeutic Targets, 2007, 11, 835-851.	3.4	54
282	Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants. ChemMedChem, 2007, 2, 445-448.	3.2	19
283	Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. ChemMedChem, 2007, 2, 987-991.	3.2	52
284	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1221-1225.	2.2	84
285	Histone deacetylase inhibitors may reduce pathogenicity and virulence inCandida albicans. FEMS Yeast Research, 2007, 7, 1371-1380.	2.3	44
286	Small-Molecule Inhibitors of Histone Acetyltransferase Activity:Â Identification and Biological Properties. Journal of Medicinal Chemistry, 2006, 49, 6897-6907.	6.4	134
287	Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6046-6056.	6.4	57
288	3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds. Journal of Chemical Information and Modeling, 2006, 46, 1420-1430.	5.4	42

#	Article	IF	Citations
289	Aroyl-Pyrrolyl Hydroxyamides: Influence of Pyrrole C4-Phenylacetyl Substitution on Histone Deacetylase Inhibition. ChemMedChem, 2006, 1, 225-237.	3.2	20
290	6-Alkylthio-4-[1-(2,6-difluorophenyl)alkyl]-1H-[1,3,5]triazin-2-ones (ADATs): Novel Regulators of Cell Differentiation and Proliferation. ChemMedChem, 2006, 1, 1073-1080.	3.2	12
291	Analytical and semipreparative high performance liquid chromatography separation of stereoisomers of novel 3,4-dihydropyrimidin-4(3H)-one derivatives on the immobilised amylose-based Chiralpak IA chiral stationary phase. Journal of Separation Science, 2006, 29, 1399-1406.	2.5	30
292	Oneâ€Pot, Highâ€Yielding Synthesis of Novel Dihydrothiazolo[3,2â€a]pyrimidinones. Synthetic Communications, 2006, 36, 495-500.	2.1	2
293	Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligandâ€"Induced Apoptosis. Cancer Research, 2006, 66, 6785-6792.	0.9	124
294	Identification of small molecules inhibitors of GCN5 histone acetyltransferase activity. Arkivoc, 2006, 2006, 24-37.	0.5	5
295	5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorganic and Medicinal Chemistry, 2005, 13, 2065-2077.	3.0	46
296	Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4656-4661.	2.2	46
297	A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. Biochemical Pharmacology, 2005, 70, 911-917.	4.4	37
298	Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Medicinal Research Reviews, 2005, 25, 261-309.	10.5	306
299	Histone Deacetylation in Epigenetics: An Attractive Target for Anticancer Therapy. ChemInform, 2005, 36, no.	0.0	0
300	Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors. Medicinal Chemistry, 2005, 1, 245-254.	1.5	23
301	Design, Synthesis, and Biological Evaluation of Sirtinol Analogues as Class III Histone/Protein Deacetylase (Sirtuin) Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7789-7795.	6.4	159
302	6-[1-(2,6-Difluorophenyl)ethyl]pyrimidinones Antagonize Cell Proliferation and Induce Cell Differentiation by Inhibiting (a Nontelomeric) Endogenous Reverse Transcriptase. Journal of Medicinal Chemistry, 2005, 48, 6776-6778.	6.4	46
303	Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry, 2005, 48, 3344-3353.	6.4	193
304	New 6-nitroquinolones: synthesis and antimicrobial activities. Il Farmaco, 2004, 59, 463-471.	0.9	19
305	Synthesis and in vitro Antimycobacterial Activity of Novel 3-(1H-Pyrrol-1-yl)-2-oxazolidinone Analogues of PNU-100480.. ChemInform, 2004, 35, no.	0.0	0
306	New 6-Nitroquinolones: Synthesis and Antimicrobial Activities.. ChemInform, 2004, 35, no.	0.0	0

#	Article	IF	Citations
307	Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1537-1541.	2.2	55
308	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2and/or -C4Substitutions on Biological Activityâ€. Journal of Medicinal Chemistry, 2004, 47, 1098-1109.	6.4	61
309	Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors. Antimicrobial Agents and Chemotherapy, 2004, 48, 1435-1436.	3.2	50
310	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studiesâ€‚". Journal of Medicinal Chemistry, 2004, 47, 1351-1359.	6.4	65
311	Computer-Aided Design, Synthesis, and Anti-HIV-1 Activity in Vitro of 2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)- ones as Novel Potent Non-Nucleoside Reverse Transcriptase Inhibitors, Also Active Against the Y181C Variant. Journal of Medicinal Chemistry, 2004, 47, 928-934.	6.4	85
312	Synthesis and biochemical evaluation of (R)-5-acyloxymethyl- and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones as new anti-monoamine oxidase (anti-MAO) agents. Arkivoc, 2004, 2004, 32-43.	0.5	5
313	Aroyl-Pyrrolyl-Hydroxy-Amides (APHAs), a Novel Family of Synthetic Histone Deacetylases Inhibitors, Are Potent Inducers of Human g-Globin Gene Expression.. Blood, 2004, 104, 1216-1216.	1.4	0
314	Role of endogenous reverse transcriptase in murine early embryo development. Molecular Reproduction and Development, 2003, 66, 225-236.	2.0	64
315	Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. Il Farmaco, 2003, 58, 231-241.	0.9	20
316	Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A. Journal of Medicinal Chemistry, 2003, 46, 4826-4829.	6.4	63
317	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures. Journal of Medicinal Chemistry, 2003, 46, 512-524.	6.4	113
318	Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide:Â A New Synthetic Histone Deacetylase Inhibitor Inducing Histone Hyperacetylation, Growth Inhibition, and Terminal Cell Differentiation. Journal of Medicinal Chemistry, 2002, 45, 1778-1784.	6.4	65
319	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as Reversible, Highly Potent, and Selective Inhibitors of Monoamine Oxidase Type A. Journal of Medicinal Chemistry, 2002, 45, 1180-1183.	6.4	35
320	A NEW FACILE AND EXPEDITIOUS SYNTHESIS OF N-HYDROXY-Nâ€²-PHENYLOCTANEDIAMJDE, A POTENT INDUCER OF TERMINAL CYTODIFFERECNTIATION. Organic Preparations and Procedures International, 2001, 33, 391-394.	1.3	40
321	3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2001, 44, 2069-2072.	6.4	79
322	Chiral resolution and molecular modeling investigation ofrac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. Chirality, 2001, 13, 75-80.	2.6	26
323	Structure-Based Design, Synthesis, and Biological Evaluation of Conformationally Restricted Novel 2-Alkylthio-6-[1-(2,6-difluorophenyl)alkyl]- 3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Journal of Medicinal Chemistry, 2001, 44, 2544-2554.	6.4	84
324	Structureâ€"Activity Relationship Studies on New DABOs: Effect of Substitutions at Pyrimidine C-5 and C-6 Positions on Anti-HIV-1 Activity. Antiviral Chemistry and Chemotherapy, 2001, 12, 37-50.	0.6	26

#	Article	IF	Citations
325	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1651-1656.	2.2	22
326	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones:Â Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives. Journal of Medicinal Chemistry, 1999, 42, 619-627.	6.4	109
327	N-[4-(1,1â€²-biphenyl)methyl]-4-(4-thiomorpholinylmethyl) benzenamines as non-oxazolidinone analogues of antimycobacterial U-100480. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1493-1498.	2.2	20
328	Arylketotetramethylene Analogues of Disoxaril with Anti-Human Rhinovirus 14 Activity. Antiviral Chemistry and Chemotherapy, 1997, 8, 235-242.	0.6	3
329	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines:Â Novel Non-Nucleoside Reverse Transcriptase Inhibitors of theS-DABO Series. Journal of Medicinal Chemistry, 1997, 40, 1447-1454.	6.4	106
330	Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments. Bioorganic and Medicinal Chemistry, 1996, 4, 1715-1724.	3.0	13
331	Methyl-2-Thienylketopolymethyleneoxyphenyl Derivatives of Alkyl-Substituted 4,5-Dihydro-Oxazoles with Anti-Human Picornavirus Activity. Antiviral Chemistry and Chemotherapy, 1996, 7, 213-220.	0.6	4
332	Pyrrolobenzodiazepines with antinociceptive activity: synthesis and pharmacological activities. European Journal of Medicinal Chemistry, 1995, 30, 593-601.	5.5	13
333	Preparation and anti-HIV-1 activity of Thio Analogues of Dichydroalkoxybenzyloxopyrimidines. Journal of Medicinal Chemistry, 1995, 38, 3258-3263.	6.4	93
334	Synthesis and Antiviral Activity of New 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs), Specific Inhibitors of Human Immunodeficiency Virus Type 1. Antiviral Chemistry and Chemotherapy, 1995, 6, 1-8.	0.6	49
335	[[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(Pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline Derivatives with Potent and Selective Antihuman Rhinovirus Activity. Journal of Medicinal Chemistry, 1995, 38, 803-809.	6.4	6
336	Antifungal Agents, II: Synthesis and Antifungal Activities of Aryl-1H-pyrrol-2-yl-1H-imidazol-1-yl-methane Derivatives with Unsaturated Chains. Archiv Der Pharmazie, 1993, 326, 539-546.	4.1	6
337	5,6-Dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepine-4,4-diacetic acid diethyl ester, an useful synthon for the synthesis of new polycyclic nitrogen systems of pharmacological interest. Journal of Heterocyclic Chemistry, 1993, 30, 897-903.	2.6	8
338	3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1. Antiviral Chemistry and Chemotherapy, 1993, 4, 361-368.	0.6	72
339	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives. Journal of Medicinal Chemistry, 1992, 35, 4533-4541.	6.4	16
340	Oneâ€pot synthesis of novel spiroâ€annelated pyroleâ€containing heterocyclic systems from suitable synthons. Journal of Heterocyclic Chemistry, 1992, 29, 241-245.	2.6	13
341	Synthesis of pyrazole analogues of isoaptazepine. Journal of Heterocyclic Chemistry, 1992, 29, 1851-1854.	2.6	5
342	Pyrrylphenylethanones Related to Cathinone and Lefetamine: Synthesis and Pharmacological Activities. Archiv Der Pharmazie, 1992, 325, 403-409.	4.1	2

#	Article	IF	Citations
343	Synthesis of new disoxaril analogues with potent and selective anti-human rhinovirus 14 activity. Bioorganic and Medicinal Chemistry Letters, 1991, 1, 575-578.	2.2	5
344	Heterocyclic system. XI. Synthesis of 1H,4Hâ€pyrazolo[4,3â€b]pyrrolizine and 2H,4Hâ€pyrazolo[4,3â€b]pyrrolizine derivatives. Journal of Heterocyclic Chemistry, 1990, 27, 1805-1808.	2.6	10
345	Spiro-[4H-pyrrolo[1,2-a][1,4]benzodiazepine-4,4â€²-piperidine] Derivatives as Potential Nootropic Agents: A Simple One-Pot Synthesis. Synthetic Communications, 1990, 20, 3537-3545.	2.1	10
346	Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogs of trichostatin A. Journal of Medicinal Chemistry, 1990, 33, 2845-2849.	6.4	25
347	Researches on Antibacterial and Antifungal Agents, X. Synthesis and Antifungal Activities of 1-{p-Methyl-Î±-[4-(1H-pyrrol-1-yl)phenyl]benzyl}azoles and Some Related Products. Archiv Der Pharmazie, 1989, 322, 369-373.	4.1	12
348	Syntheses of 3b,4,6,7-Tetrahydro-5h,9h-pyrazino [2,1-c] phyrolo[1,2-a] [1,4] benzodiazepine, a valuable precursor of potential central nervous system agents. Tetrahedron, 1989, 45, 2763-2772.	1.9	18
349	Synthesis of a new tetracyclic system related to aptazapine (CGS 7525A) by one-pot double annelation. Tetrahedron Letters, 1988, 29, 6471-6474.	1.4	16
350	The effect of mTOR blockers on japanese quail ovarian granulosa cell functions. Endocrine Abstracts, 0, , 1-1.	0.0	0
351	Medicinal Chemistry â€“ Research and Publishing. ChemistryViews, 0, , .	0.0	0